A search for a light charged Higgs boson (H^{+}) decaying to a W boson and a CP-odd Higgs boson (A) in final states with eμμ or μμμ is performed using data from pp collisions at sqrt[s]=13 TeV, recorded by the CMS detector at the LHC and corresponding to an integrated luminosity of 35.9 fb^{-1}. In this search, it is assumed that the H^{+} boson is produced in decays of top quarks, and the A boson decays to two oppositely charged muons. The presence of signals for H^{+} boson masses between 100 and 160 GeV and A boson masses between 15 and 75 GeV is investigated. No evidence for the production of the H^{+} boson is found. Upper limits at 95% confidence level are obtained on the combined branching fraction for the decay chain, t→bH^{+}→bW^{+}A→bW^{+}μ^{+}μ^{-}, of 1.9×10^{-6} to 8.6×10^{-6}, depending on the masses of the H^{+} and A bosons. These are the first limits for these decay modes of the H^{+} and A bosons.
This study explains the modeling of synthesized membranes using the Donnan Steric Pore model (DSPM) based on the Extended Nernst Planck Equation (ENP). Conventionally, structural parameters required to predict the performance of the membranes were determined through tedious experimentation, which in this study are found using a new MATLAB technique. A MATLAB program is used to determine the unknown structural parameters such as effective charge density (Xd), effective pore radius (rp), and effective membrane thickness to porosity ratio (Δx/Ak) by using the single solute rejection and permeation data. It was found that the model predicted the rejection of studied membranes accurately, with the E5C1 membrane exceeding the others (E5, E5C5) for rejection of single and divalent salt's aqueous solutions. The rejection of 100 ppm aqueous solution of NaCl for E5C1 was around 60%, whereas, for an aqueous solution of 100 ppm, CaCl2 rejection reached up to 80% at 10 bar feed pressure. The trend of salt rejection for all three membranes was found to be in the following order: E5C1 > E5C5 > E5, confirming that their structural parameters-controlled ion transport in these membranes. The structural parameters, such as effective pore radius, effective membrane thickness to porosity ratio, and effective charge density for the best performing membrane, i.e., E5C1, were determined to be 0.5 nm, 16 μm, and -6.04 mol/m3,respectively. Finally, it can be asserted that this method can be used to predict the real performance of membranes by significantly reducing the number of experiments previously required for the predictive modeling of nanofiltration-type membranes.
In this present experimental study, geopolymer cement is developed using high calcium fly ash and used in the production of one-part alkali-activated binders. At 8-16 percent of the total precursor materials, the HCFA was activated with anhydrous sodium metasilicate powder and cured in ambient condition. Five mixtures of one-part geopolymer paste were intended at a steady w/b proportion. Density, flowability, setting time, compressive strength, splitting tensile strength and molar ratio impact were envisaged. It was observed that the setting time of the designed one-part geopolymer paste decreases with higher activator content. The experimental findings showed that the resistance of one-part geopolymer cement paste increases with comparatively greater activator content. However, raising the granular activator beyond 12 percent by fly ash weight decreases the strength and workability of the established one-part geopolymer cement. The optimum mix by weight of the fly ash was discovered to be 12 percent (i.e. 6 percent Na2O). At 28 days of curing, one-part alkali-activated paste recorded the greatest compressive strength of almost 50 MPa. The density of the one-part geopolymer paste is nearly the same regardless of the mixes. Microstructural assessment by FESEM, FTIR and XRD has shown that the established geopolymer paste includes quartz, pyrrhotite, aluminosilicate sodium and hydrate gels of calcium aluminosilicate. Based on the experimental information acquired, it can be deduced that the strength growth of one-part geopolymer cement is similar to that of Portland cement.
Background: Hepatitis B virus (HBV) infection has many faces. Precore and core promoter mutants resemble inactive carrier status. The identification of hepatitis B core antigen (HBcAg) in hepatocytes may have variable clinical significance. The present study was undertaken to detect HBcAg in chronic hepatitis B (CHB) patients and to assess the efficacy of detection system by indirect immunofluorescence (IIF) and indirect immunoperoxidase (IIP).
Materials and methods: The study was done in 70 chronic HBV-infected patients. Out of 70 patients, eight (11.4%) were hepatitis B e antigen (HBeAg) positive and 62 (88.57%) were HBeAg negative. Hepatitis B core antigen was detected by indirect immunofluorescence (IIF) and indirect immunoperoxidase (IIP) methods in liver tissue.
Results: All HBeAg positive patients expressed HBcAg by both IIF and IIP methods. Out of 62 patients with HBeAg-negative CHB, HBcAg was detected by IIF in 55 (88.7%) patients and by IIP in 51 (82.26%) patients. A positive relation among viral load and HBcAg detection was also found. This was more evident in the case of HBeAg negative patients and showed a positive relation with HBV DNA levels.
Conclusion: Hepatitis B core antigen can be detected using the IIF from formalin fixed paraffin block preparation and also by IIP method. This seems to reflect the magnitudes of HBV replication in CHB.
How to cite this article: Raihan R, Tabassum S, Al-Mahtab M, Nessa A, Jahan M, Kabir CMS, Kamal M, Aguilar JC. Hepatitis B Core Antigen in Hepatocytes of Chronic Hepatitis B: Comparison between Indirect Immunofluorescence and Immunoperoxidase Method. Euroasian J Hepato-Gastroenterol 2015;5(1):7-10.
The global emergence and dissemination of multidrug-resistant Gram-negative superbugs, particularly carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae, lead to the limited effectiveness of antibiotics for treating nosocomial infections. In most cases, polymyxins are the last resort therapy, and these antibiotics must be used intelligently to prolong their efficacy in clinical practice. Polymyxin B and colistin (polymyxin E) were introduced prior to modern drug regulation, and the majority of the 'old' drug information is unreliable. Recent pharmacokinetic data do not support the renal dose adjustment of intravenous (IV) polymyxin B as suggested by the manufacturer, and this drug must be scaled by the total body weight. Whereas IV colistin is formulated as an inactive prodrug, colistin methanesulfonate (CMS) has different pharmacokinetic profiles than polymyxin B. To achieve maximum efficacy, CMS should be administered as a loading dose scaled to body weight and a maintenance dose according to the renal profiles. Polymyxin combination therapy is suggested due to a sub-therapeutic plasma concentration in a significant proportion of patients and a high incidence of polymyxin hetero-resistance among Gram-negative superbugs. In conclusion, polymyxins must be reserved as a last resort and should be wisely used when truly indicated.